Market Overview

Gilead Announces Results from Two Phase 3 Stribild HIV Studies

Gilead Sciences (NASDAQ: GILD) today announced two-year (96-week) results
from two pivotal Phase 3 studies (Studies 102 and 103) evaluating the
company's newest single tablet HIV regimen, StribildTM
(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg), among treatment-naïve patients with HIV-1
infection. Data show that Stribild was non-inferior after two years of
treatment to two standard of care HIV regimens, Atripla®
(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300
mg) in Study 102 and a protease-based regimen of ritonavir-boosted
atazanavir plus Truvada® (emtricitabine and tenofovir
disoproxil fumarate) in Study 103. These results were presented today in
an oral session at the 11th International Congress on Drug Therapy in
HIV Infection (HIV11) in Glasgow,

See full press release

Posted-In: News Guidance Management

 

Related Articles (GILD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters